Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00871546 | SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715) | terminated | Phase 2 | 8 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 7, 2015 | clinicaltrials |
| NCT00250718 | Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach | terminated | Phase 2 | 17 | New Mexico Cancer Research AllianceOTHER | 1 | Aug 3, 2015 | clinicaltrials |
| NCT00274651 | A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas(PXD101-CLN-6) | terminated | Phase 2 | 53 | Valerio TherapeuticsINDUSTRY | 5 | Jul 28, 2015 | clinicaltrials |
| NCT00363779 | Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Jul 21, 2015 | clinicaltrials |
| NCT01497275 | Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma | terminated | Phase 2 | 5 | Duke UniversityOTHER | 1 | Jul 15, 2015 | clinicaltrials |
| NCT00431340 | A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma | terminated | Phase 2 | 4 | Valerio TherapeuticsINDUSTRY | 1 | Jul 8, 2015 | clinicaltrials |
| NCT00543582 | MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma | terminated | Phase 2 | 23 | Mirati Therapeutics Inc.INDUSTRY | 1 | Jul 1, 2015 | clinicaltrials |
| NCT00129415 | Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions | terminated | Phase 1 / Phase 2 | 28 | University of MichiganOTHER | 1 | May 22, 2015 | clinicaltrials |
| NCT00395967 | AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone | terminated | Phase 2 | 5 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | May 1, 2015 | clinicaltrials |
| NCT01062230 | Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 6 | University of ArkansasOTHER | 1 | Apr 6, 2015 | clinicaltrials |
| NCT00210392 | VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy | terminated | Phase 2 | 12 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 1 | Mar 30, 2015 | clinicaltrials |
| NCT00077961 | Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL | terminated | Phase 1 / Phase 2 | 49 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 26, 2015 | clinicaltrials |
| NCT00185679 | Haploid Allogeneic Transplant Using the CliniMACS System | terminated | Phase 2 | 13 | Ginna LaportOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT02353468 | Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant | terminated | Phase 2 | 3 | University of Colorado, DenverOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT02353572 | Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | 3 | University of Colorado, DenverOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT00051701 | Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 61 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 5, 2015 | clinicaltrials |
| NCT00529503 | A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL | terminated | Phase 2 | 151 | Seagen Inc.INDUSTRY | 10 | Feb 25, 2015 | clinicaltrials |
| NCT01302366 | A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma | terminated | Phase 2 | 20 | NYU Langone HealthOTHER | 1 | Feb 12, 2015 | clinicaltrials |
| NCT00916045 | Pilot Study of Unrelated Cord Blood Transplantation | terminated | Phase 2 | 40 | King's College Hospital NHS TrustOTHER | 1 | Feb 11, 2015 | clinicaltrials |
| NCT00719901 | Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Jan 12, 2015 | clinicaltrials |
| NCT01078441 | Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Jan 12, 2015 | clinicaltrials |
| NCT01653418 | Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation(V-BEAM) | terminated | Phase 2 | 10 | Washington University School of MedicineOTHER | 1 | Oct 15, 2014 | clinicaltrials |
| NCT00288067 | Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2014 | clinicaltrials |
| NCT00675428 | Study of Natalizumab in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 6 | BiogenINDUSTRY | 1 | Sep 19, 2014 | clinicaltrials |
| NCT00240162 | PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma | terminated | Phase 2 | 21 | Washington University School of MedicineOTHER | 1 | Sep 17, 2014 | clinicaltrials |
| NCT01914718 | Dose-adjusted EPOCH-R in MYC Positive DLBCL | terminated | Phase 2 | 26 | Fudan UniversityOTHER | 1 | Aug 20, 2014 | clinicaltrials |
| NCT01397591 | Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma | terminated | Phase 2 | 3 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 30, 2014 | clinicaltrials |
| NCT01078922 | Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas | terminated | Phase 2 | 11 | Oncology Specialists, S.C.OTHER | 1 | Jul 16, 2014 | clinicaltrials |
| NCT01466868 | Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma(AKTIL) | terminated | Phase 2 | 22 | Centre Leon BerardOTHER | 1 | Jul 10, 2014 | clinicaltrials |
| NCT02079519 | A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma | terminated | Phase 2 | 10 | Hoffmann-La RocheINDUSTRY | 1 | Jul 8, 2014 | clinicaltrials |
| NCT00365274 | SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00089076 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | terminated | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00387426 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | terminated | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00872300 | PHA-739358 for the Treatment of Multiple Myeloma | terminated | Phase 2 | 7 | Nerviano Medical SciencesINDUSTRY | 2 | May 28, 2014 | clinicaltrials |
| NCT00100711 | Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | Phase 2 | 27 | Pharmacyclics LLC.INDUSTRY | 1 | May 23, 2014 | clinicaltrials |
| NCT00183950 | Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy | terminated | Phase 1 / Phase 2 | 12 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00183976 | Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas | terminated | Phase 2 | 15 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00183989 | Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma | terminated | Phase 2 | 30 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00383565 | FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | May 20, 2014 | clinicaltrials |
| NCT00293111 | Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM) | terminated | Phase 2 | 30 | CephalonINDUSTRY | 1 | May 12, 2014 | clinicaltrials |
| NCT00510887 | Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma | terminated | Phase 2 | 14 | Duke UniversityOTHER | 1 | May 12, 2014 | clinicaltrials |
| NCT00588822 | Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance | terminated | Phase 2 | 21 | Mayo ClinicOTHER | 1 | May 6, 2014 | clinicaltrials |
| NCT01902862 | An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma | terminated | Phase 2 | 7 | Janssen-Cilag G.m.b.HINDUSTRY | 1 | Apr 1, 2014 | clinicaltrials |
| NCT00863395 | Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma(CTCL) | terminated | Phase 1 / Phase 2 | 6 | University of MinnesotaOTHER | 1 | Mar 31, 2014 | clinicaltrials |
| NCT00441168 | Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma | terminated | Phase 2 | 30 | Janssen-Cilag International NVINDUSTRY | 7 | Mar 21, 2014 | clinicaltrials |
| NCT00396383 | Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation | terminated | Phase 2 | 9 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00499239 | A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) | terminated | Phase 1 / Phase 2 | 32 | Gilead SciencesINDUSTRY | 3 | Feb 4, 2014 | clinicaltrials |
| NCT00308087 | Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma(PREMIER) | terminated | Phase 2 | 75 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | Dec 27, 2013 | clinicaltrials |
| NCT00412919 | Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma | terminated | Phase 2 | 7 | Bayside HealthOTHER_GOV | 1 | Dec 16, 2013 | clinicaltrials |
| NCT01090973 | Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) | terminated | Phase 2 | 1 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 16, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Aug 7, 2015source: clinicaltrials